Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997015303) TREATING DISORDERS MEDIATED BY VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/015303 International Application No.: PCT/US1996/016309
Publication Date: 01.05.1997 International Filing Date: 21.10.1996
Chapter 2 Demand Filed: 25.04.1997
IPC:
A61K 31/00 (2006.01) ,A61K 31/155 (2006.01) ,A61K 31/415 (2006.01) ,A61K 31/4174 (2006.01) ,A61K 31/4178 (2006.01) ,A61K 31/498 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
155
Amidines (), e.g. guanidine (H2N-C(NH)-NH2), isourea (HNC(OH)NH2), isothiourea (HNC(SH)-NH2)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4174
Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4178
not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
498
Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
Applicants:
CORNELL RESEARCH FOUNDATION, INC. [US/US]; Suite 105 20 Thornwood Drive Ithaca, NY 14850, US
Inventors:
REGUNATHAN, Soundararajan; US
REIS, Donald, J.; US
Agent:
SPECTOR, Eric, S.; Jones, Tullar & Cooper, P.C. P.O. Box 2266 Eads Station Arlington, VA 22202, US
Priority Data:
08/548,97327.10.1995US
Title (EN) TREATING DISORDERS MEDIATED BY VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
(FR) TRAITEMENT D'AFFECTIONS RESULTANT DE LA PROLIFERATION DES MUSCLES LISSES DES PAROIS VASCULAIRES
Abstract:
(EN) Disorders mediated by vascular smooth muscle proliferation are treated by administering a vascular smooth muscle antiproliferative effective amount of an I2 imidazoline receptor agonist. The disorders include atherosclerosis, risk of blockage of artery after coronary angioplasty or blood vessel injury from non-angioplasty cause, and proliferative diabetic retinopathy. I2 imidazoline receptor agonists include idazoxan, UK 14,304, naphazoline, cirazoline and agmatine.
(FR) On peut traiter les affections résultant de la prolifération des muscles lisses des parois vasculaires en administrant une dose à effet antiprolifération desdits muscles, d'un agoniste du récepteur I2 de l'imidazoline. Lesdites affections englobent l'athérosclérose, le risque de blocage des artères après une angioplastie coronarienne, ou des lésions des vaisseaux non liées à une angioplastie, et la rétinopathie diabétique proliférante. Les agonistes de du récepteur I2 de l'imidazoline comprennent l'idazoxan, l'UK 14,304, la naphazoline, la cirazoline et l'agmatine.
Designated States: JP
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: English (EN)
Filing Language: English (EN)